White Paper

Key Stages In mRNA-Based Therapeutic Development From Discovery To Commercialization

iStock-1295693740-covid-coronavirus-vaccine-mrna

Fueled by the success of the messenger ribonucleic acid (mRNA)-based COVID-19 vaccines, RNA-based medicines are poised to revolutionize the pharmaceutical industry. These therapeutics have provided definitive proof of the therapeutic efficacy and safety of this new modality which has catalyzed interest and investment across the industry. This is leading to the development of RNA therapeutics beyond prophylactic vaccines and towards breakthrough treatments for cancer, rare diseases and more.

It is important to note that there are some unique challenges and risks in each step of the drug development process for this rapidly growing class of drugs, and success lies in considering the path to commercialization at the earliest stage possible. Each phase of mRNA-based therapeutic development consists of specific goals, steps, and end points. Learn the fundamentals of manufacturing mRNA-lipid nanoparticle (LNP) drug products from discovery through to commercialization.

 

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: